156 related articles for article (PubMed ID: 3024351)
1. Short duration combination chemotherapy in the treatment of small cell lung cancer.
Dorward AJ; Banham SW; Hutcheon AW; Ahmedzai S; Cunningham D; Gregor A; Soukop M; Stack BH; Mackay NS; Kaye SB
Thorax; 1986 Sep; 41(9):688-91. PubMed ID: 3024351
[TBL] [Abstract][Full Text] [Related]
2. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
5. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
6. Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.
Bishop JF; Kefford R; Raghavan D; Zalcberg J; Stuart-Harris R; Ball D; Olver IN; Friedlander M; Bull C; Yuen K
Cancer Chemother Pharmacol; 1990; 25(5):367-70. PubMed ID: 2155064
[TBL] [Abstract][Full Text] [Related]
7. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
8. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
9. Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer.
McIllmurray MB; Bibby RJ; Taylor BE; Ormerod LP; Edge JR; Wolstenholme RJ; Willey RF; O'Reilly JF; Horsfield N; Johnson CE
Thorax; 1989 Mar; 44(3):215-9. PubMed ID: 2539655
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
11. [Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer].
Saito H; Kawatsu H; Saka H; Yamamoto M; Takagi E; Tsunekawa H; Kawachi H; Nagura E; Sakai S; Nishiwaki K
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1909-13. PubMed ID: 2838000
[TBL] [Abstract][Full Text] [Related]
12. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
[TBL] [Abstract][Full Text] [Related]
13. Intensive alternating chemotherapy regimen in small cell carcinoma of the lung.
Markman M; Abeloff MD; Berkman AW; Waterfield WC
Cancer Treat Rep; 1985 Feb; 69(2):161-6. PubMed ID: 2982490
[TBL] [Abstract][Full Text] [Related]
14. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
Spiro SG; Souhami RL; Geddes DM; Ash CM; Quinn H; Harper PG; Tobias JS; Partridge M; Eraut D
Br J Cancer; 1989 Apr; 59(4):578-83. PubMed ID: 2540788
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
Aisner J; Whitacre M; Van Echo DA; Wiernik PH
Cancer Treat Rep; 1982 Feb; 66(2):221-30. PubMed ID: 6275987
[TBL] [Abstract][Full Text] [Related]
16. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.
Evans WK; Osoba D; Feld R; Shepherd FA; Bazos MJ; DeBoer G
J Clin Oncol; 1985 Jan; 3(1):65-71. PubMed ID: 2981293
[TBL] [Abstract][Full Text] [Related]
17. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
Bleehen NM; Girling DJ; Machin D; Stephens RJ
Br J Cancer; 1993 Dec; 68(6):1150-6. PubMed ID: 8260367
[TBL] [Abstract][Full Text] [Related]
18. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
20. Induction chemo-radiotherapy and maintenance alternating chemotherapy for small cell lung cancer.
Tummarello D; Guidi F; Torresi U; Isidori P; Rossi A; Dazzi C; Cellerino R
Acta Oncol; 1990; 29(4):417-20. PubMed ID: 2167701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
